Abstract
Natural and synthetic electrophilic compounds have been shown to activate the antioxidant protective Nrf2 (nuclear factor erythroid 2‐related factor 2)/heme oxygenase‐1 (HO‐1) axis in cells and tissues. Here, we tested the ability of different isoxazoline‐based electrophiles to up‐regulate Nrf2/HO‐1. The potency of activation is dependent on the leaving group at the 3‐position of the isoxazoline nucleus, and an additional ring on the molecule limits the Nrf2/HO‐1 activating properties. Among the synthetized compounds, we identified 3‐bromo‐5‐phenyl‐4,5‐dihydroisoxazole 1 as the derivative with best activating properties in THP‐1 human monocytic cells. We have confirmed that the target of our compounds is the Cys151 of the BTB domain of Keap1 by using mass spectrometry analyses and X‐ray crystallography. Our findings demonstrate that these compounds affect the Nrf2/HO‐1 axis and highlight a positive activity that can be of relevance from a therapeutic perspective in inflammation and infection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
